Terlipressin: Difference between revisions – Wikipedia

5
Terlipressin: Difference between revisions – Wikipedia


 

Line 1: Line 1:

{{Short description|Chemical compound}}

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}

{{Infobox drug

{{Infobox drug

| verifiedrevid = 470602469

| verifiedrevid = 470602469

Line 71: Line 72:

Terlipressin is [[indicated]] to improve kidney function in adults with [[hepatorenal syndrome]] with rapid reduction in kidney function.<ref name=”Terlivaz FDA label”>{{cite web | title=Terlivaz- terlipressin injection, powder, lyophilized, for solution | website=DailyMed | date=19 September 2022 | url= | access-date=27 September 2022 | archive-date=28 September 2022 | archive-url=https://web.archive.org/web/20220928050107/ | url-status=live }}</ref>

Terlipressin is [[indicated]] to improve kidney function in adults with [[hepatorenal syndrome]] with rapid reduction in kidney function.<ref name=”Terlivaz FDA label”>{{cite web | title=Terlivaz- terlipressin injection, powder, lyophilized, for solution | website=DailyMed | date=19 September 2022 | url= | access-date=27 September 2022 | archive-date=28 September 2022 | archive-url=https://web.archive.org/web/20220928050107/ | url-status=live }}</ref>

Indications for use include norepinephrine-resistant [[septic shock]]<ref name=”OBrien”>{{cite journal |vauthors=O’Brien A, Clapp L, Singer M |title=Terlipressin for norepinephrine-resistant septic shock |journal=[[The Lancet|Lancet]] |volume=359 |issue=9313 |pages=1209–10 |year=2002 |pmid=11955542 |doi=10.1016/S0140-6736(02)08225-9|s2cid=38463837 }}</ref> although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock<ref>{{Cite journal |last=Evans |first=Laura |last2=Rhodes |first2=Andrew |last3=Alhazzani |first3=Waleed |last4=Antonelli |first4=Massimo |last5=Coopersmith |first5=Craig M. |last6=French |first6=Craig |last7=Machado |first7=Flávia R. |last8=Mcintyre |first8=Lauralyn |last9=Ostermann |first9=Marlies |last10=Prescott |first10=Hallie C. |last11=Schorr |first11=Christa |last12=Simpson |first12=Steven |last13=Wiersinga |first13=W. Joost |last14=Alshamsi |first14=Fayez |last15=Angus |first15=Derek C. |date=November 2021 |title=Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 |url= |journal=Critical Care Medicine |language=en-US |volume=49 |issue=11 |pages=e1063 |doi=10.1097/CCM.0000000000005337|doi-access=free }}</ref> and [[hepatorenal syndrome]].<ref name=”Uriz”>{{cite journal |vauthors=Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J |title=Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome |journal=J Hepatol |volume=33 |issue=1 |pages=43–8 |year=2000 |pmid=10905585 |doi=10.1016/S0168-8278(00)80158-0}}</ref> In addition, it is used to treat bleeding [[esophageal varices]].<ref name=”Ioannou”>{{cite journal |vauthors=Ioannou G, Doust J, Rockey D |title=Terlipressin for acute esophageal variceal hemorrhage |journal=Cochrane Database Syst Rev |issue= 1|pages=CD002147 |year= 2003|pmid=12535432 |doi=10.1002/14651858.CD002147 |editor1-last=Ioannou |editor1-first=George N|pmc=7017851 }}</ref>

Indications for use include norepinephrine-resistant [[septic shock]]<ref name=”OBrien”>{{cite journal |vauthors=O’Brien A, Clapp L, Singer M |title=Terlipressin for norepinephrine-resistant septic shock |journal=[[The Lancet|Lancet]] |volume=359 |issue=9313 |pages=1209–10 |year=2002 |pmid=11955542 |doi=10.1016/S0140-6736(02)08225-9|s2cid=38463837 }}</ref> although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock<ref>{{ journal |=Evans |=Laura |last2=Rhodes |first2=Andrew |last3=Alhazzani |first3=Waleed |last4=Antonelli |first4=Massimo |last5=Coopersmith |first5=Craig M. |last6=French |first6=Craig |last7=Machado |first7=Flávia R. |last8=Mcintyre |first8=Lauralyn |last9=Ostermann |first9=Marlies |last10=Prescott |first10=Hallie C. |last11=Schorr |first11=Christa |last12=Simpson |first12=Steven |last13=Wiersinga |first13=W. Joost |last14=Alshamsi |first14=Fayez |last15=Angus |first15=Derek C. |date=November 2021 |title=Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 |url= |journal=Critical Care Medicine |language=en-US |volume=49 |issue=11 |pages= |doi=10.1097/CCM.0000000000005337|doi-access=free }}</ref> and [[hepatorenal syndrome]].<ref name=”Uriz”>{{cite journal |vauthors=Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J |title=Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome |journal=J Hepatol |volume=33 |issue=1 |pages=43–8 |year=2000 |pmid=10905585 |doi=10.1016/S0168-8278(00)80158-0}}</ref> In addition, it is used to treat bleeding [[esophageal varices]].<ref name=”Ioannou”>{{cite journal |vauthors=Ioannou G, Doust J, Rockey D |title=Terlipressin for acute esophageal variceal hemorrhage |journal=Cochrane Database Syst Rev |issue= 1|pages=CD002147 |year= 2003|pmid=12535432 |doi=10.1002/14651858.CD002147 |editor1-last=Ioannou |editor1-first=George N|pmc=7017851 }}</ref>

==Contraindications==

==Contraindications==

Line 77: Line 78:

== Society and culture ==

== Society and culture ==

Terlipressin is available in United States,<ref>{{Cite journal |title=FDA approves treatment to improve kidney function in adults with hepatorenal syndrome |journal=FDA |date=14 September 2022 |url= |url-status=live |archive-url=https://web.archive.org/web/20230210043353/ |archive-date=2023-02-10 |access-date=2023-02-21}}</ref> New Zealand,<ref> {{Webarchive|url= |date=2021-12-20 }} {{Bare URL PDF|date=March 2022}}</ref> Australia, the European Union,<ref>{{Cite web|url= India, Pakistan & UAE. It is sold under various brand names including Glypressin and Terlivaz.

Terlipressin is available in United States,<ref>{{ journal |title=FDA approves treatment to improve kidney function in adults with hepatorenal syndrome |journal=FDA |date=14 September 2022 |url= |url-status=live |archive-url=https://web.archive.org/web/20230210043353/ |archive-date=2023-02-10 |access-date=2023-02-21}}</ref> New Zealand,<ref> {{Webarchive|url= |date=2021-12-20 }} {{Bare URL PDF|date=March 2022}}</ref> Australia, the European Union,<ref>{{ web|url= India, Pakistan & UAE. It is sold under various brand names including Glypressin and Terlivaz.

==References==

==References==

Chemical compound

Terlipressin
Trade names Terlivaz
AHFS/Drugs.com International Drug Names
Routes of
administration
Intravenous
ATC code
Legal status
Protein binding ~30%
  • 1-{[(4R,7S,10S,13S,16S,19R)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-N-(2-amino-2-oxoethyl)-L-lysinamide

CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard 100.035.149 Edit this at Wikidata
Formula C52H74N16O15S2
Molar mass 1227.38 g·mol−1
3D model (JSmol)
  • O=C(N)CNC(=O)[C@@H](NC(=O)[C@H]4N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1)Cc2ccc(O)cc2)Cc3ccccc3)CCC(=O)N)CC(=O)N)CCC4)CCCCN

  • InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 checkY
  • Key:BENFXAYNYRLAIU-QSVFAHTRSA-N checkY
  (verify)

Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist.[2]

Terlipressin was approved for medical use in the United States in 2022.[2][4][5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[5][6]

Medical uses[edit]

Terlipressin is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.[2]

Indications for use include norepinephrine-resistant septic shock[7] although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock[8] and hepatorenal syndrome.[9] In addition, it is used to treat bleeding esophageal varices.[10]

Contraindications[edit]

Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia.[2] Terlipressin may cause fetal harm when used during pregnancy.[2]

Society and culture[edit]

Terlipressin is available in United States,[11] New Zealand,[12] Australia, the European Union,[13] India, Pakistan & UAE. It is sold under various brand names including Glypressin and Terlivaz.

References[edit]

  1. ^ “FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)”. nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ a b c d e f “Terlivaz- terlipressin injection, powder, lyophilized, for solution”. DailyMed. 19 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
  3. ^ “Drug Approval Package: Terlivaz”. United States. Food and Drug Administration (FDA). 7 October 2022. Retrieved 4 December 2022.
  4. ^ “Drug Approval Package: Terlivaz”. United States. Food and Drug Administration (FDA). 7 October 2022. Retrieved 23 January 2023.
  5. ^ a b “Advancing Health Through Innovation: New Drug Therapy Approvals 2022”. United States. Food and Drug Administration (FDA). 10 January 2023. Retrieved 22 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ New Drug Therapy Approvals 2022 (PDF). United States. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  7. ^ O’Brien A, Clapp L, Singer M (2002). “Terlipressin for norepinephrine-resistant septic shock”. Lancet. 359 (9313): 1209–10. doi:10.1016/S0140-6736(02)08225-9. PMID 11955542. S2CID 38463837.
  8. ^ Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC (November 2021). “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021”. Critical Care Medicine. 49 (11): e1063–e1143. doi:10.1097/CCM.0000000000005337. PMID 34605781.
  9. ^ Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J (2000). “Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome”. J Hepatol. 33 (1): 43–8. doi:10.1016/S0168-8278(00)80158-0. PMID 10905585.
  10. ^ Ioannou G, Doust J, Rockey D (2003). Ioannou GN (ed.). “Terlipressin for acute esophageal variceal hemorrhage”. Cochrane Database Syst Rev (1): CD002147. doi:10.1002/14651858.CD002147. PMC 7017851. PMID 12535432.
  11. ^ “FDA approves treatment to improve kidney function in adults with hepatorenal syndrome”. FDA. 14 September 2022. Archived from the original on 2023-02-10. Retrieved 2023-02-21.
  12. ^ Archived 2021-12-20 at the Wayback Machine[bare URL PDF]
  13. ^ “Terlipressin”. Archived from the original on 2019-06-26. Retrieved 2018-01-23.

External links[edit]

  • “Terlipressin”. Drug Information Portal. United States. National Library of Medicine.

Disasters Expo USA, is proud to be supported by Inergency for their next upcoming edition on March 6th & 7th 2024!

The leading event mitigating the world’s most costly disasters is returning to the Miami Beach

Convention Center and we want you to join us at the industry’s central platform for emergency management professionals.
Disasters Expo USA is proud to provide a central platform for the industry to connect and
engage with the industry’s leading professionals to better prepare, protect, prevent, respond
and recover from the disasters of today.
Hosting a dedicated platform for the convergence of disaster risk reduction, the keynote line up for Disasters Expo USA 2024 will provide an insight into successful case studies and
programs to accurately prepare for disasters. Featuring sessions from the likes of The Federal Emergency Management Agency,
NASA, The National Aeronautics and Space Administration, NOAA, The National Oceanic and Atmospheric Administration, TSA and several more this event is certainly providing you with the knowledge
required to prepare, respond and recover to disasters.
With over 50 hours worth of unmissable content, exciting new features such as their Disaster
Resilience Roundtable, Emergency Response Live, an Immersive Hurricane Simulation and
much more over just two days, you are guaranteed to gain an all-encompassing insight into
the industry to tackle the challenges of disasters.
By uniting global disaster risk management experts, well experienced emergency
responders and the leading innovators from the world, the event is the hub of the solutions
that provide attendees with tools that they can use to protect the communities and mitigate
the damage from disasters.
Tickets for the event are $119, but we have been given the promo code: HUGI100 that will
enable you to attend the event for FREE!

So don’t miss out and register today: https://shorturl.at/aikrW

And in case you missed it, here is our ultimate road trip playlist is the perfect mix of podcasts, and hidden gems that will keep you energized for the entire journey

-

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More